Cerebrospinal Fluid (CSF) Concentration of Coenzyme Q10 in Clinical Practice, A Breaking News Finding in Humans

R.B. Singh¹ and A. Naini²,*

¹Halberg Hospital and Research Institute, Moradabad, India; ²Department of Neurology, Columbia University Medical Center, New York, NY

Abstract: There is significant interest in coenzyme Q₁₀ (CoQ₁₀) as a potential treatment for neurodegenerative diseases and in its promise as a neuroprotectant. Experimental studies indicate that CoQ₁₀ can protect against brain disorders by inhibiting neuronal damage. There is a need to demonstrate CSF levels of CoQ₁₀ in humans.

Subjects and Methods: After clearance from the hospital ethical committee, all of the subjects presenting with a suspicion of neurological diseases were asked to give written informed consent for lumbar puncture for testing of CSF. CoQ₁₀ concentration in CSF was examined by HPLC with electrochemical detection system at the Division of Molecular Neurogenetics, College of Physicians and Surgeons, New York, USA. Clinical and laboratory data were obtained from all of the patients (n=38) to confirm clinical diagnosis. CAT scan of the head was done in all of the patients presenting with seizures and stroke. All CSF specimens were examined for cells, sugar and proteins and those suspected of being contaminated with blood were excluded from study.

Results: The age varied between 17 to 60 years and the number of males (n=16) were less than females (n=21). Patients were suffering from epileptic seizures (n=19), tuberculous meningitis (n=5) and stroke (n=4). The rest of the 9 patients presented with headache of non-neurological condition with or without fever. The CSF concentration of CoQ₁₀ was significantly lower among these subjects; mean ± SD (0.59 ± 0.12 ng/ml), which appears to represent the normal level of CoQ₁₀ in healthy subjects. The concentration of CoQ₁₀ in CSF tended to be higher among patients with TBM (1.27 ± 0.60 ng/ml), seizures (1.26 ± 0.34 ng/ml) and stroke (0.83 ± 0.20 ng/ml) compared to subjects without neurological problem. These findings indicate that there is greater release of CoQ₁₀ or increased synthesis in the tissues possibly to fight against oxidative stress caused by brain disorders.

Conclusions: This study shows that the level of CoQ₁₀ in the CSF is substantially lower than that in serum by three orders of magnitude and tends to be elevated under pathological conditions associated with brain injury. Further studies in a larger number of subjects are necessary to confirm our findings.

Key Words: Brain, ubiquinone, degenerative diseases, antioxidant, mitochondrial myopathy.

INTRODUCTION

Coenzyme Q₁₀ (CoQ₁₀), a lipid component of virtually all cell membranes, has several important biological functions. In the mitochondria, CoQ₁₀ transfers electrons from complex I and complex II to complex III of respiratory chain. It is also an antioxidant [1], a membrane stabilizer [2], and in adipose tissues, it serves as a cofactor for uncoupling proteins [3].

CoQ₁₀ deficiency has been observed in patients with Parkinson’s disease, Huntington’s disease, tuberous sclerosis, motor neuron disease, and cerebellar ataxia, CoQ₁₀ supplementation may be useful in these conditions [4-7]. CoQ₁₀ deficiency has also been observed in patients receiving statins, which is known to cause myopathy and rhabdomyolysis [8-10]. Coenzyme CoQ₁₀ administration increases, brain mitochondrial concentrations and exerts neuroprotective effects [11, 12].

*Address correspondence to this author at the Molecular Neurogenetics, Columbia University, 1150 St. Nicholas Avenue, 3rd Floor, Rm 318, NY, NY 10032, USA; Tel: 212-305-2118; Fax: 212-305-3986; E-mail: abn2@columbia.edu

CoQ₁₀ is responsible for energy generation through the mitochondrial respiratory chain and because of its antioxidant properties, indirect support for pathogenetic role of CoQ₁₀ deficiency is provided from data from patients with idiopathic, primary CoQ₁₀ deficiency in mitochondrial myopathies [13-15]. These patients have a mitochondrial encephalomyopathy, most commonly presenting as a autosomal recessive spinocerebellar atrophy syndrome. A rarer myopathic variant combines central nervous system signs; ataxia, epilepsy, and mental retardation, with a mitochondrial myopathy dominated by recurrent rhabdomyolysis and myoglobinuria which are also an adverse effect of statin. A circadian rhythm in the coenzyme concentrations and a histochmical demonstration of a circadian rhythm of succinate dehydrogenase in rat pineal gland, and influence of CoQ₁₀ addition has also been observed [16].

Naini and coworkers in 19 new patients with cerebellar ataxia established the existence of an ataxic syndrome due to primary CoQ₁₀ deficiency and responsive to CoQ₁₀ treatment [6]. Since all patients presented with cerebellar ataxia and cerebellar atrophy, this poses the possibility of a selective vulnerability of the cerebellum to CoQ₁₀ deficiency. These workers found that in rats, cerebellum had the lowest level of...
CoQ10 and the level of CoQ10 was much higher in brain than in blood or visceral tissue, such as heart, liver or kidney indicating that it has vital role in brain function and degeneration [6]. However, there is lack of evidence, to demonstrate the cerebrospinal fluid levels of CoQ10 in normal subjects, compared to neurological degenerative diseases.

SUBJECTS AND METHODS

This is a case control study conducted in the Department of Internal Medicine, Halberg Hospital and Research Institute, Moradabad, India. It has a institutional ethic committee involving experts from other institutions and public. After clearance from the hospital ethic committee, all the subjects presenting with a suspicion of neurological diseases(n=37) were asked to give written informed consent for lumber puncture for testing of CSF. CoQ10 concentration in CSF was examined by HPLC with electrochemical detection after hexane extraction and purification. Briefly, CSF specimens were centrifuged at 3000 x g and 4°C for 15 min and a 2-mL aliquot was subjected to hexane extraction essentially as described by Lang e al. (1986). The HPLC system consisted of model 582 pump, model 542 autosampler, Coulorochem II detector, 5011 Analytical Cell (E1 set at -600 Volts and E2 set at +450 Volts), and 5020 Guard Cell set at +800 Volts and positioned between autosampler and column. All the HPLC system components were from ESA (ESA, Inc., Shelmsford, MA). For the CoQ10 assay, the extracted CoQ10 was dissolved in 150 μL of 1-propanol and a 50-μL portion was directly injected onto the HPLC. The separation was achieved on a C18 reversed-phase column (Waters Corporation, Milford, MA) using a mobile phase containing 50 mM sodium acetate in a mixture of ethanol, methanol, 2-propyl alcohol, and acetic acid (50%, 47%, 1.5%, and 1.5% respectively). Data acquisition and processing was performed utilizing EZ chrom HPLC software (Scientific Software Inc., Pleasanton, CA).

Biochemical Method

Clinical and laboratory data were obtained in all the patients (n=38) to confirm the clinical diagnosis. CAT scan head was done in all the patients presenting with seizures and stroke. CSF was examined for cells, sugar and proteins in all the patients. Values were excluded in 5 subjects (11.7 to 26.9 ng/ml) due to possible contamination with blood.

RESULTS

The age varied between 17 to 60 years and the number of males were fewer than females (n=14 vs 19). Patients were suffering from epileptic seizures (n=15), tuberculous meningitis (n=4) and stroke (n=4). Ten patients presented with headache of non-neurological condition with or without fever. The CSF concentration of CoQ10 was significantly lower among these subjects; mean ± SEM (0.59 ± 0.12 ng/ml), which appears to be normal level of CoQ10 in healthy subjects. The concentration of CoQ10 in CSF was greater among patients with TBM (1.27±0.60 ng/ml), seizures (1.26±0.34 ng/ml) and stroke (0.83±0.20 ng/ml) compared to subjects without neurological problem. However, the differences were not significant (ANOVA P>0.05).

DISCUSSION

Here we report data presenting the levels of CoQ10 in control subjects (subjects with no known neurological ab-normalities) and in three groups of patients suffering some form of neurological disorder associated with brain injury. To our knowledge, this is the first report on the levels of CoQ10 in the CSF in these groups of patients, which compared to serum, is less by about three orders of magnitude. Such low levels of CoQ10 can only be reliably measured by HPLC with a very sensitive electrochemical detector system. The observation that the subjects, who presented with minimal brain disorders also had the lowest levels of CoQ10 in their CSF probably indicates that under pathological conditions associated with neurodegeneration, there is a rise in CSF CoQ10 as a result of either tissue damage and release from the cell or to increased synthesis as a cell response to free radical production caused by injury. In this context, it has recently been shown that increased levels of CoQ10 may protect cells from chemotherapy-induced oxidative stress [17].

In recent years, the possible beneficial effects of CoQ10 for the treatment of a wide variety of diseases, including disorders associated with neurodegeneration, has been investigated. In 1999, Singh and Singh used CoQ10 for the treatment of patients with motor neuron disease and polymyositis (18). However, in most of these studies, CoQ10 levels were measured in the plasma or the serum and few studies have assessed intracellular CoQ10 concentration in patients. In the plasma, CoQ10 is transported with the very low density lipoprotein (VLDL) fraction hence, it’s levels are closely related to the plasma VLDL levels which can be affected by both the disease processes and by dietary factors. Moreover, whereas the cellular level of CoQ10 is dependent mostly on endogenous biosynthesis [18], the plasma level has been suggested as representing the equilibrium between CoQ10 absorption and synthesis [19]. Taken together, it appears that the plasma level of CoQ10 can not always be regarded as a true indicator of cellular levels. Therefore, in studies in which the cellular levels of CoQ10 and its changes under pathological conditions are investigated, tissues other than serum or plasma are more desirable. In this context, when the role of CoQ10 in diseases such as Parkinson’s disease, Alzimer’s disease, Huntington’s disease, or ALS is investigated, CSF is probably a true indicator of cellular level.

In conclusion, this is the first report of CoQ10 levels in the CSF as measured by highly sensitive HPLC with electrochemical detection system. These preliminary data indicate that (1) the level of CoQ in the CSF is less than in the serum by three orders of magnitude and (2) CSF levels tend to increase after injury. Obviously, with the availability of the methodology, further studies can be conducted to confirm and expand these preliminary findings.

REFERENCES


